<sup>18</sup>F-氟化钠PET/CT诊断肿瘤骨转移应用进展

张胤; 陈跃; 张胤; 陈跃

doi:10.3760/cma.j.issn.1673-4114.2015.01.020

[1]

Czernin J, Satyamurthy N, Schiepers C. Molecular mechanisms of bone ¹⁸F-NaF deposition[J]. J Nucl Med, 2010, 51(12):1826-1829.

[2]

Blau M, Nagler W, Bender MA. Fluorine-18:a new isotope for bone scanning[J]. J Nucl Med, 1962, 3:332-4.

[3]

Segall G, Delbeke D, Stabin MG, et al. SNM practice guideline for Sodium F-18-Fluoride PET/CT bone scans 1.0[J]. J Nuc Med, 2010, 51(11):1813-1820.

[4]

Segall GM. PET/CT with sodium ¹⁸F-fluoride for management of patients with prostate cancer[J]. J Nucl Med, 2014, 55(4):531-533.

[5]

Frost ML, Compston JE, Goldsmith D, et al. ¹⁸F-fluoride positron emission tomography measurements of regional bone formation in hemodialysis patients with suspected adynamic bone disease[J]. Calcif Tissue Int, 2013, 93(5):436-447.

[6]

Grant FD, Fahey FH, Packard AB, et al. Skeletal PET with F-18-fluoride:Applying new technology to an old tracer[J]. J Nuclr Med, 2008, 49(1):68-78.

[7]

Caldarella C, Treglia G, Giordano A, et al. When to perform positron emission tomography/computed tomography or radionuclide bone scan in patients with recently diagnosed prostate cancer[J]. Cancer Manag Res, 2013, 5(6):123-131.

[8]

Tateishi U, Morita S, Taguri M, et al. A meta-analysis of ¹⁸F-Fluoride positron emission tomography for assessment of metastatic bone tumor[J]. Ann Nucl Med, 2010, 24(7):523-531.

[9]

Damle NA, Bal C, Bandopadhyaya GP, et al. The role of ¹⁸F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma:a comparison with FDG PET/CT and ^99mTc-MDP bone scan[J]. Jpn J Radiol, 2013, 31(4):262-269.

[10]

Bastawrous S, Bhargava P, Behnia F, et al. Newer PET application with an old tracer:role of ¹⁸F-NaF skeletal PET/CT in oncologic practice[J]. Radiographics, 2014, 34(5):1295-1316.

[11]

Doot RK, Muzi M, Peterson LM, et al. Kinetic analysis of ¹⁸F-fluoride PET images of breast cancer bone metastases[J]. J Nucl Med, 2010, 51(4):521-527.

[12]

Tarnawska-Pierscińska M, Holody L, Braziewicz J, et al. Bone metastases diagnosis possibilities in studies with the use of ¹⁸F-NaF and ¹⁸F-FDG[J]. Nucl Med Rev Cent East Eur, 2011, 14(2):105-108.

[13]

Kawaguchi M, Tateishi U, Shizukuishi K, et al. ¹⁸F-fluoride uptake in bone metastasis:morphologic and metabolic analysis on integrated PET/CT[J]. Ann Nucl Med, 2010, 24(4):241-247.

[14]

Schirrmeister, H, Guhlmann, A, Kotzerke, J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography[J]. J Clin Oncol, 1999, 17(8):2381-2389.

[15]

Yoon SH, Kim KS, Kang SY, et al. Usefulness of ¹⁸F-fluoride PET/CT in breast cancer patients with osteosclerotic bone metastases[J]. Nucl Med Mol Imaging, 2013, 47(1):27-35.

[16]

Iagaru A, Mittra E, Mosci C, et al. Combined F-18-Fluoride and F-18-FDG PET/CT scanning for evaluation of malignancy:results of an international multicenter trial[J]. J NuclMed, 2013, 54(2):176-183.

[17]

Lin FI, Rao JE, Mittra ES, et al. Prospective comparison of combined ¹⁸F-FDG and ¹⁸F-NaF PET/CT vs. ¹⁸F-FDG PET/CT imaging for detection of malignancy[J]. Eur J Nucl Med Mol Imaging, 2012, 39(2):262-270.

[18]

Schirrmeister H, Glatting G, Hetzel J. Prospective evaluation of the clinical value of planar bone scans, SPECT, and ¹⁸F-labeled NaF PET in newly diagnosed lung cancer[J]. J Nucl Med, 2001, 42(12):1800-1804.

[19]

Even-Sapir E, Metser U, Mishani E, et al. The detection of bone metastases in patients with high-risk prostate cancer:Tc-99m-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, F-18-fluoride PET, and F-18-fluoride PET/CT[J]. J Nucl Med, 2006, 47(2):287-297.

[20]

Hillner BE, Siegel BA, Hanna L, et al. Impact of ¹⁸F-fluoride PET in patients with known prostate cancer:initial results from the National Oncologic PET Registry[J]. J Nucl Med, 2014, 55(4):574-581.

[21]

Jadvar H, Desai B, Ji L, et al. Prospective evaluation of ¹⁸F-NaF and ¹⁸F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer[J]. Clin Nucl Med, 2012, 37(7):637-643.

[22]

Mosavi F, Johansson S, Sandberg DT, et al. Whole-body diffusion-weighted MRI compared with F-18-NaF PET/CT for detection of bone metastases in patients with High-Risk prostate carcinoma[J]. Am J Roentgenol, 2012, 199(5):1114-1120.

[23]

Hillner BE, Siegel BA, Hanna L, et al. Impact of ¹⁸F-Fluoride PET on intended management of patients with cancers other than prostate cancer:results from the national oncologic PET registry[J]. J Nucl Med, 2014, 55(7):1054-1061.

[24]

Sharma P, Karunanithi S, Chakraborty PS, et al. ¹⁸F-Fluoride PET/CT for detection of bone metastasis in patients with renal cell carcinoma:a pilot study[J]. Nucl Med Commun, 2014, 35(12):1247-1253.

[25]

Chan SC, Wang HM, Ng SH, et al. Utility of ¹⁸F-Fluoride PET/CT and ¹⁸F-FDG PET/CT in the detection of bony metastases in heightened-risk head and neck cancer patients[J]. J Nucl Med, 2012, 53(11):1730-1735.

[26]

Ota N, Kato K, Iwano S, et al. Comparison of ¹⁸F-fluoride PET/CT, ¹⁸F-FDG PET/CT and bone scintigraphy(planar and SPECT)in detection of bone metastases of differentiated thyroid cancer: a pilot study[J/OL]. Br J Radiol, 2014, 87(1034): 20130444[2014-11-30]. http://www. ncbi. nlm. nih. gov/pubmed/?term=24297809.

[27]

Chakraborty D, Bhattacharya A, Mete UK, et al. Comparison of ¹⁸F fluoride PET/CT and ^99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma[J]. Clin Nucl Med, 2013, 38(8):616-621.

[28]

Avery R, Kuo PH. ¹⁸F Sodium fluoride PET/CT detects osseous metastases from breast cancer missed on FDG PET/CT with marrow rebound[J]. Clin Nucl Med, 2013, 38(9):746-748.

[29]

Sharma S. Imaging and intervention in prostate cancer:Current perspectives and future trends[J]. Indian J Radiol Imaging, 2014, 24(2):139-148.

[30]

Iagaru A, Young P, Mittra E, et al. Pilot prospective evaluation of ^99mTc-MDP scintigraphy, ¹⁸F NaF PET/CT, ¹⁸F FDG PET/CT and whole-body MRI for detection of skeletal metastases[J/OL]. Clin Nucl Med, 2013, 38(7): e290-e296[2014-11-30]. http://www. ncbi. nlm. nih. gov/pubmed/?term=23455520.

[31]

Iagaru A, Mittra E, Dick DW, et al. Prospective evaluation of ^99mTc MDP scintigraphy, ¹⁸F NaF PET/CT, and ¹⁸F FDG PET/CT for detection of skeletal metastases[J]. Mol Imaging Biol, 2012, 14(2):252-259.

[32]

Shen CT, Qiu ZL, Han TT, et al. Performance of ¹⁸F-Fluoride PET or PET/CT for the detection of bone metastases:a meta-analysis[J]. Clin Nucl Med, 2015, 40(2):103-110.

[33]

Iagaru A, Mittra E, Yaghoubi SS, et al. Novel strategy for a cocktail ¹⁸F-fluoride and ¹⁸F-FDG PET/CT scan for evaluation of malignancy:results of the pilot-phase study[J]. J Nucl Med, 2009, 50(4):501-505.

[34]

Sampath SC, Sampath SC, Mosci C, et al. Detection of osseous metastasis by ¹⁸F-NaF/¹⁸F-FDG PET/CT versus CT alone[J/OL]. Clin Nucl Med, 2015, 40(3): e173-177[2014-11-30]. http://www. ncbi. nlm. nih. gov/pubmed/?term=25140557.

[35]

Harisankar CN, Agrawal K, Bhattacharya A, et al. F-18 fluoro-deoxy-glucose and F-18 sodium fluoride cocktail PET/CT scan in patients with breast cancer having equivocal bone SPECT/CT[J]. Indian J Nucl Med, 2014, 29(2):81-86.

[36]

王俊起, 高硕. PET评价骨转移瘤[J].国际放射医学核医学杂志, 2006, 30(2):87-90.

[37]

Drubach LA, Connolly SA, Palmer EL, et al. Skeletal scintigraphy with ¹⁸F-NaF PET for the evaluation of bone pain in children[J]. Am J Roentgenol, 2011, 197(3):713-719.

[38]

Lee SJ, Lee WW, Kim SE. Bone positron emission tomography with or without CT is more accurate than bone scan for detection of bone metastasis[J]. Korean J Radiol, 2013, 14(3):510-519.